NCT01888367View on ClinicalTrials.gov

Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

445

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Surgical Site Infections
Interventions
DRUG

DFA-02 Antibiotic Gel

DRUG

DFA-02 Placebo Gel

Trial Locations (31)

Unknown

Florence

Sheffield

Phoenix

Tucson

Laguna Hills

Los Angeles

Aurora

Washington D.C.

Jacksonville

Miami

Tampa

Weston

Columbus

Powder Springs

Indianaoplis

Alexandria

New Orleans

Burlington

Worcester

Minneapolis

Jackson

Las Vegas

Albany

New York

Chapel Hill

Columbus

Oklahoma City

Hershey

Bellaire

Nassau Bay

Burlington

Sponsors
All Listed Sponsors
collaborator

Duke Clinical Research Institute

OTHER

lead

Dr. Reddy's Laboratories Limited

INDUSTRY

NCT01888367 - Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery | Biotech Hunter | Biotech Hunter